

Mapping phosphorylation of peptide biomarkers corresponding with glioblastoma tumours using data-dependent acquisition and multi-reflecting time-of-flight mass spectrometry

Authors: Matthew E. Daly¹, Lee A. Gethings¹, Christopher J. Hughes¹, Richard Lock¹, Hamida Mussa² and Nelofer Syed²

Affiliations: ¹Waters Corporation, Wilmslow, UK. ²Faculty of Medicine, Department of Brain Sciences, Imperial College London, London, UK

INTRODUCTION

Glioblastoma is an aggressive form of brain tumor with little therapeutic options available, and correspondingly the 5-year survival rate remains <10% of those diagnosed, whilst the median life expectancy is 15 months¹. Phosphorylation is a key post-translational modification (PTM) that is involved in numerous processes, such as activation of key enzymes/kinases for example. Hence, phosphorylation sites are important targets for the regulation and development of glioma and may offer insight for new targeted therapies to perturb specific cellular pathways.²

Profiling of phosphorylated residues using mass spectrometry can be problematic due to the labile nature of the phosphoryl group. For example, during collision induced dissociation the group can be lost (H_3PO_4 or $\text{HPO}_3 + \text{H}_2\text{O}$) resulting in a neutral loss of -98Da. When combined with data independent approaches (DIA) approaches and complex spectra, it can make identification of phosphorylated residues difficult. However, utilising data dependent acquisition (DDA) mode allows relation of the precursor m/z and that resulting from a neutral loss to that of the quadrupole set mass, facilitating identification of phosphorylated peptides.³

Here, we describe an LC-MS workflow using the Xevo™ MRT Mass Spectrometer; a novel benchtop high resolution, high mass accuracy platform for accurately and characterizing post-translational modifications whilst also providing corresponding quantitative data (Figure 1).




Figure 1. Schematic of the Xevo MRT MS showing the newly implemented collision cell alongside the gridless ToF demonstrating multiple reflections of the ion beam achieving up to 100,000 FWHM mass resolution.

METHODS

Adult primary glioblastoma cell lines (four) were treated with arginine deprivation therapy using arginine degrading enzyme ADI-PEG20. Treated and untreated cell lines were lysed in the presence of protease and phosphatase inhibitors (Figure 2). Samples were then reduced, alkylated and tryptically digested prior to enrichment using Fe(iii)-NTA spin columns. The LC-MS platform consisted of an ACQUITY™ Premier Chromatography System that was specially coated to minimise non-specific adsorption thereby increasing phosphopeptide recovery coupled to a Xevo MRT Mass Spectrometer. Enriched phosphopeptides were separated using a 30 minute gradient. MS data were collected using the DDA mode, where the top 15 most intense ions per survey scan were selected for respective MS/MS.

LC Conditions

System	ACQUITY Premier System
Column	ACQUITY Premier Peptide CSH™ Column 2.1 x 100 mm (p/n 186009488)
Column temperature	45 °C
Solvents	A; H ₂ O + 0.1% FA, B; MeCN + 0.1% FA
Flow	150 µL/min
Gradient	1 to 35% B over 30 minutes, followed by a wash at 85% B

MS Conditions

System	Xevo MRT Mass Spectrometer
Acquisition mode	Data dependent acquisition
MS Survey range	50-2000 <i>m/z</i>
MS Survey scan rate	10 Hz
MS/MS ions	Top 15 ions
MS/MS scan rate	4 Hz
Peak detection	Charge state detection; 2+, 3+, 4+
Dynamic peak exclusion	Acquire and exclude for 30 seconds, 500 mDa window
Collision energy	Charge state recognition collision energy ramp




Figure 2. Fragmentation spectra of matched primary ions plus neutral losses of peptide with sequences AGDLEDpSPKRPK (top) LGSLPVLSPTpSLPpSPLPATLETPVPAFLK (bottom). Loss of phosphoryl group observed as a neutral loss of 98Da are shown in green.

RESULTS

Phosphorylated peptides were selectively enriched and subject to analysis by data-dependent acquisition on the Xevo MRT Mass Spectrometer. Data generated from the enrichment workflow and MS analysis were processed using ProteinLynx Global Server (PLGS).

Due to the relatively low proportional amount of phosphorylated peptides compared to unmodified sequences, enrichment prior to analysis was necessary in order to characterise these low abundant molecules. Therefore, Fe(iii)-NTA spin columns were utilised to selectively bind phosphopeptides, allowing unmodified peptides to flow through. Initial experiments indicated an abundance of phosphorylated peptides in the enriched sample identified through neutral loss of 98 Da and therefore the enrichment strategy was applied to a full study sample set. Data dependent acquisition on the Xevo MRT Mass Spectrometer successfully switched on the top 15 most intense ions and provided excellent MS/MS spectra for site localisation of phosphorylated residues (Figure 2). The fast-scanning capabilities, combined with low interscan-delay and high resolution of the Xevo MRT Mass Spectrometer facilitated identification of over 320 proteins from phosphorylated peptides (Figure 3). Identified proteins were subjected to pathway analysis using MetaCore™ which revealed, as expected, pathways associated with neurological disorders and regulation of cytoskeleton proteins. Process networks indicated to be involved were also focussed around translation, cytoskeleton regulation and protein folding. Finally, translational networks showed differences between the untreated and treated cells due to the administration of metabolic therapy.




Figure 3. MS1 spectra of the doubly charged peptide with sequence KQSLGELIGTLNAK (m/z 811.92835) and AALLKASPK (m/z 489.77270). Mass resolution was >71,000 FWHM and mass error was <500ppb.

DISCUSSION

Identification of phosphopeptides is of particular difficulty due to their low abundance in biological samples and labile nature of the modification during CID leading to inability to sufficiently localise sites of phosphorylation. Nevertheless, employing enrichment strategies coupled to DDA on a benchtop Xevo MRT Mass Spectrometer successfully profiled the phosphoproteome of human glioblastoma cell lines before and after treatment with a metabolic therapy.

Mapping the effect of metabolic therapies on protein activation through network analysis provides insights and shapes future strategies for drug discoveries. In this case, the metabolic therapy applied to the glioblastoma cell lines demonstrated marked differences in protein identifications compared to the untreated cell lines. Key areas of interest were identified as including activation pathways involving kinases as expected, but also neurological pathways and regulation of cytoskeleton proteins.

Further work to understand the downstream implications of these effects is currently underway to elucidate the mechanism of action of the metabolic therapy.

CONCLUSION

Phosphopeptide enrichment from human glioblastoma cell lines was successfully implemented using Fe(III)-NTA spin columns. The ACQUITY Premier System demonstrated excellent non-adsorption of phosphopeptides and in tandem with data dependent acquisition successfully profiled and localised sites of phosphorylation. The Xevo MRT Mass Spectrometer provided mass resolution of >70,000 FWHM at fast scan speeds of 20 Hz and allowed for confident identification of both precursor and product ions.

REFERENCES

1. Poon, M.T.C., Sudlow, C.L.M., Figueroa, J.D. et al. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. *Sci Rep* 10, 11622 (2020). <https://doi.org/10.1038/s41598-020-68011-4>
2. Qin, A., Musket, A., Musich, P. R., Schweitzer, J. B., Xie, Q. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?, *Neuro-Oncology Advances*, Volume 3, Issue 1, January-December 2021, vdab133, <https://doi.org/10.1093/noajnl/vdab133>
3. Srinivasan, A.; Sing, J. C.; Gingras, A.-C.; Röst, H. L. Improving Phosphoproteomics Profiling Using Data-Independent Mass Spectrometry. *Journal of Proteome Research* 2022, 21 (8), 1789-1799. DOI: 10.1021/acs.jproteome.2c00172.
4. Hajji, N.; SGarcia-Revilla, J.; Soto, M. S.; Perryman, R.; Symington, J.; Quarles, C. C.; Healey, D. R.; Guo, Y.; Orta-Vazquez, M. L.; Mateos-Cordero, S.; et al. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. *J Clin Invest* 2022, 132 (6). DOI: 10.1172/JCI142137

Waters™

Waters, ACQUITY, Xevo, UPLC, and CSH are trademarks of Waters Corporation. MetaCore is a trademark of Clarivate. XCMS is a trademark of The Scripps Research Institute. All other trademarks are the property of their respective owners.

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
waters.com